India, March 8 -- Q32 Bio Inc. (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy of Dermatology (AAD) Meeting in Orlando, FL.
Results presented in the AAD late-breaker demonstrated bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA).
Durable, ongoing responses in multiple patients through the week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggest a potential for remittive effect. Multiple inbound patient requests to re-initiate dosing have been receive.
In the Phase ...